Identifying the predictors of estimated glomerular filtration rate after partial nephrectomy with a nonlinear regression model.

PURPOSE: To evaluate the effect of partial nephrectomy on renal function and to identify predictors of estimated glomerular filtration rate (eGFR) at 6 months after partial nephrectomy. METHODS: Medical data of 154 consecutive patients who underwent partial nephrectomy for a renal mass between January 2015 and March 2020 were retrospectively analysed. The primary outcome measure was eGFR at 6 months postoperatively. An ordinary least regression analysis using a restricted cubic spline for continuous variables was performed to examine the association between primary outcome measure and candidate predictors. RESULTS: Of the patients, 66 (42.9%) were females and 88 (57.1%) were males with a median age of 60 (range, 50 to 67) years. The median baseline eGFR was 90.40 (range, 74.96 to 102.97) mL/min/1.73 m2 , while the median eGFR at 6 months was 77.12 (range, 61.06 to 91.93) mL/min/1.73 m2 (P < .001). Baseline eGFR (regression coefficient (ß) = 22.7, 95%CI: 18.8 to 26.5, P < .001) was found to be most significant predictor with the postoperative eGFR levels at 6 months. In addition, advanced tumour size (ß = -3.17, 95%CI: -5.33 to -1.01, P < .001) and presence of hypertension (ß = -3.48, 95%CI: -6.96 to -0.003, P = .049) were also found to be inversely associated with the postoperative eGFR levels at 6 months. CONCLUSION: Baseline eGFR values, tumour size, and presence of hypertension are significant predictors of eGFR values in the mid-term in patients undergoing partial nephrectomy.

Relationship between plasma Atherogenic index and final pathology of Bosniak III-IV renal masses: a retrospective, single-center study.

BACKGROUND: There is an increased incidence of renal cell carcinoma (RCC) in patients with metabolic syndrome who usually have high levels of serum triglyceride (TG) and low high-density lipoprotein-cholesterol (HDL-C). Plasma atherogenic index (PAI) is the logarithmic ratio of serum TG level to HDL-C and related to cardiovascular diseases. In this study, we aimed to determine the accuracy of PAI in determining renal malignancy in localized renal masses preoperatively. METHODS: Totally 169 patients who were diagnosed with Bosniak III-IV lesions by imaging modalities and treated in our hospital with partial or radical nephrectomy were retrospectively analyzed using institutional renal cancer database between 2013 and 2018. Preoperative images were evaluated by two experienced radiologists. The patients were divided into two groups according to their postoperative pathological diagnosis as malignant or benign tumors. The PAI of each patient was calculated and the statistical significance of PAI in predicting malignancy for renal masses was analyzed using uni- and multivariable analyses. RESULTS: Of patients, 109 (64.5%) were males and 60 (35.5%) were females with a median age of 61 (33-84) years. Median tumor size was 6.5 (2-18) cm. Pathological diagnosis was malignant in 145 (85.8%) and benign in 24 (14.2%) patients. There was no statistically significant difference in serum TG levels between malignant and benign cases (p > 0.05). The HDL-C levels were significantly lower in malignant cases (p = 0.001). Median PAI value was 0.63 (0.34-1.58) and significantly higher in malignant cases (p = 0.003). The PAI cut-off value for malignancy was ≥0.34. The sensitivity was calculated as 88.2% and specificity as 45.8%, the positive predictive value as 90.8, negative predictive value as 39.3, and odds ratio as 6.37 (95% CI: 2.466-16.458). In multivariable analysis, gender, smoking status, and hypertension had no effect on malignancy, whereas PAI and HDL-C were independent risk factors (p = 0.003 and p = 0.003, respectively). The risk of malignancy was 5.019 times higher, when PAI was > 0.34 (95% CI: 1.744-14.445) in multivariable logistic regression analysis. CONCLUSIONS: The PAI can be used as a predictive tool in suspicion of malignant renal masses. In case of a benign pathology, PAI levels may be encouraging for surgeons for nephron-sparing surgery.

What is the role of CellDetect® in detecting and monitoring bladder cancer?

PURPOSE: Cystoscopy is the gold standard method for diagnosing and monitoring bladder cancer but it is costly, invasive, and operator-dependant. The aim is to compare the diagnostic efficacy of CellDetect® with urine cytology based on cystoscopic findings. METHODS: A total of 181 patients undergoing cystoscopy for bladder cancer follow-up or any reason were studied with cytology and CellDetect® by taking an urine sample before cystoscopy. Patients who had any kind of bladder procedure in less than 1 month, doubtful cystoscopy results, previous pathology of Tis or carcinoma in situ (CIS), urinary stones, and patients with urinary catheters or bladder diversions were excluded. Cytologic and CellDetect® results were compared based on cystoscopic findings and sensitivity and specifity analyses were done for each method. RESULTS: For low-grade tumors, the sensitivity of CellDetect® was 66.7% and the sensitivity of cytology was 16.7% with a significant difference (p < 0.05). For high-grade tumors, there were no significant difference between CellDetect® and cytology. Generally, CellDetect® had better sensitivity in both case and control groups. CONCLUSION: The promising results of CellDetect® particularly in low-grade tumors gives the potential for this novel stain to go widespread. Larger series, meta-analyses, and reviews need to support this topic in order to put CellDetect® into daily practice.